Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | MEDI1191 with durvalumab in advanced solid tumors

Eduardo Castañón • 16 Apr 2023
AACR 2023
General Antibodies Checkpoint Inhibitors Durvalumab MEDI1191

Eduardo Castañón, MD, Universidad de Navarra, Pamplona, Spain, presents findings from a Phase I trial (NCT03946800) of MEDI1191, a lipid nanoparticle-formulated mRNA encoding IL-12 injected intratumorally, with durvalumab. The investigational combination was well tolerated in a majority of patients, and the overall response rate (ORR) was lower than expected, possible due to a small cohort. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eduardo Castañón

0:47
Activating the TME with MEDI1191, a lipid nanoparticle with mRNA encoding IL-12
Eduardo Castañón • 16 Apr 2023

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals